Study shows promise in repairing damaged myelin
A scientific breakthrough provides new hope for millions of people living with multiple sclerosis. Researchers at OHSU have developed a compound that stimulates repair of the protective sheath that covers nerve cells in the brain and spinal cord.
The discovery, involving mice genetically engineered to mimic multiple sclerosis, published today in the journal JCI Insight.
MS is a chronic condition that affects an estimated 2.3 million people worldwide. In MS, the sheath covering nerve fibers in the brain and spinal cord becomes damaged, slowing or blocking electrical signals from reaching the eyes, muscles and other parts of the body. This sheath is called myelin. Although myelin can regrow through exposure to thyroid hormones, researchers have not pursued thyroid hormone therapies due to unacceptable side effects.
Although several treatments and medications alleviate the symptoms of MS, there is no cure.
“There are no drugs available today that will re-myelinate the de-myelinated axons and nerve fibers, and ours does that,” said senior author Tom Scanlan, Ph.D., professor of physiology and pharmacology in the OHSU School of Medicine.
Co-author Dennis Bourdette, M.D., chair of neurology in the OHSU School of Medicine and director of the OHSU Multiple Sclerosis Center, said he expects it will be a few years before the compound advances to the stage of a clinical trial involving people. Yet the discovery provides fresh hope for patients in Oregon and beyond.
“It could have a significant impact on patients debilitated by MS,” Bourdette said.
The discovery reported today, if ultimately proven in clinical trials involving people, appears to accomplish two important goals:
- Myelin repair with minimal side effects: The study demonstrated that the compound – known as sobetirome – promotes remylenation without the severe side effects of thyroid hormone therapy. Thyroid hormone therapy has not been tried in people because chronic elevated exposure known as hyperthyroidism harms the heart, bone, and skeletal muscle.
- Efficient delivery: Researchers developed a new derivative of sobetirome (Sob-AM2) that penetrates the blood brain barrier, enabling a tenfold increase in infiltration to the central nervous system.
“We’re taking advantage of the endogenous ability of thyroid hormone to repair myelin without the side effects,” said lead author Meredith Hartley, Ph.D., an OHSU postdoctoral researcher in physiology and pharmacology.
Co-authors credited the breakthrough to a collaboration that involved scientists and physicians with expertise ranging across neurology, genetics, advanced imaging, physiology and pharmacology.
Potential as a ‘total game-changer’
One patient said the research could be a “total game-changer” for people with MS.
Laura Wieden, 48, has lived with multiple sclerosis since being diagnosed in 1995. The daughter of Portland advertising executive Dan Wieden, she is the namesake and board member of the Laura Fund for Innovation in Multiple Sclerosis, which funded much of the research involved in the study published today.
“I am really optimistic,” Wieden said. “I hope that this will be literally a missing link that could just change the lives of people with MS.”
Scanlan originally developed sobetirome as a synthetic molecule more than two decades ago, initially with an eye toward using it to lower cholesterol. In recent years, Scanlan’s lab adapted it as a promising treatment for a rare metabolic disease called adrenoleukodystrophy, or ALD.
Six years ago, Bourdette suggested trying the compound to repair myelin in MS.
Supported by funding provided through the Laura Fund and the National Multiple Sclerosis Society, the team turned to Ben Emery, Ph.D., an associate professor of neurology in the OHSU School of Medicine. Emery, an expert who previously established his own lab in Australia focused on the molecular basis of myelination, genetically engineered a mouse model to test the treatment.
A ‘Trojan horse’
With promising early results, researchers wanted to see if they could increase the amount of sobetirome that penetrated into the central nervous system.
They did so through a clever trick of chemistry known as a prodrug strategy.
Scientists added a chemical tag to the original sobetirome molecule, creating an inert compound called Sob-AM2. The tag’s main purpose is to eliminate a negative charge that prevents sobetirome from efficiently penetrating the blood-brain barrier. Once Sob-AM2 slips past the barrier and reaches the brain, it encounters a particular type of brain enzyme that cleaves the tag and converts Sob-AM2 back into sobetirome.
“It’s a Trojan horse type of thing,” Scanlan said.
Researchers found that the treatment in mice not only triggered myelin repair, but they also measured substantial motor improvements in mice treated with the compound.
“The mouse showed close to a full recovery,” Scanlan said.
Scientists say they are confident that the compound will translate from mice to people. To that end, OHSU has licensed the technology to Llama Therapeutics Inc., a biotechnology company in San Carlos, California. Llama is working to advance these molecules toward human clinical trials in MS and other diseases.
Bourdette said even though it may not help his patients today, he’s optimistic the discovery eventually will move from the lab into the clinic.
“Right now, what it means is hope,” he said.
Learn more: Study shows promise in repairing damaged myelin
The Latest on: Myelin repair
via Google News
The Latest on: Myelin repair
- New Imaging Agent of Myelin for Earlier MS Diagnosis, Myeliviz, Entering Clinical Testingon January 29, 2020 at 5:05 am
Preclinical studies showed that Myeliviz can directly detect and quantify myelin changes in the brain ... MS and monitor disease progression and repair processes.” Myeliviz’s potential will ...
- Dose-dependent effect of cannabinoid WIN-55,212-2 on myelin repair following a demyelinating insulton January 17, 2020 at 3:50 am
CNS myelination is impaired when the drug is administered at 1 mg/Kg while 0.5 mg/Kg favours neuroprotection and myelin repair Here we evaluated the consequences of the administration of the ...
- Scientists discover 'molecular switch' that can help repair damage to central nervous systemon January 12, 2020 at 2:14 am
"Myelin regeneration holds tremendous potential to improve function. We showed when we block the PAR1 receptor, neurological healing is much better and happens more quickly. In many cases, the nervous ...
- A molecular switch for repairing damage in central nervous system disorders discoveredon January 10, 2020 at 4:00 pm
In many cases, the nervous system does have a good capacity for innate repair. This sets the stage for development of new clinically relevant myelin regeneration strategies." Myelin acts like a ...
- A molecular switch for repairing central nervous system disorderson January 9, 2020 at 4:00 pm
"We have not used the drug in animals yet, and it is not ready to put in patients for the purpose of myelin repair. Using cell culture systems, we are showing that this has the potential to ...
- The Neural Androgen Receptoron December 30, 2019 at 4:00 pm
Fluorescent conjugated antibodies (Alexa Fluor® 488 or 546, Invitrogen) were also used. For myelin basic protein immunostaining, paraffin-embedded sections were subjected to antigen retrieval by ...
- Which research results in mice will help humans with MS? Now there’s a way to tellon December 29, 2019 at 4:00 pm
“Our primary motivation was to try to understand, at a molecular level, how the human cells responsible for synthesizing myelin differ from their much-better-studied mouse counterparts.” MS and some ...
- The Neural Androgen Receptoron December 28, 2019 at 4:00 pm
We also identify the neural androgen receptor as a novel therapeutic target ... also efficiently promoted myelin repair. These data establish the efficacy of androgens as remyelinating agents ...
- Why the brain slows at 40on November 18, 2019 at 11:07 pm
But while myelin builds up during adolescence, when does production slow enough that we fall behind in the race to repair fraying, older insulation? Enter the new research. First, Bartzokis ...
- Diabetes drug offers hope of new treatment for multiple sclerosison October 2, 2019 at 9:33 am
If this relatively simple, cheap and available drug can rejuvenate myelin repair in humans as well, then this may be really helpful in neurodegenerative diseases such as multiple sclerosis where ...
via Bing News